XML 32 R20.htm IDEA: XBRL DOCUMENT
v3.21.2

Operating Segments | 6 Months Ended
--- | ---
Jun. 30, 2021
Segment Reporting [Abstract] |
Operating Segments | 11. Operating Segments In accordance with ASC 280, “Segment Reporting”, the Company defines an operating segment as a business activity: (1) from which we may earn revenue and incur expenses; (2) whose operating results are regularly reviewed by the chief operating decision maker (“CODM”) to make decisions about resources to be allocated to the segment and assess its performance; and (3) for which discrete financial information is available. Our reporting segments are defined as below: TREATMENT SEGMENT, which includes:
| - | nuclear, low-level radioactive, mixed waste (containing both hazardous and low-level radioactive constituents), hazardous and non-hazardous waste treatment, processing and disposal services primarily through four uniquely licensed and permitted treatment and storage facilities; and
| - | Research & Development (“R&D”) activities to identify, develop and implement innovative waste processing techniques for problematic waste streams.
SERVICES SEGMENT, which includes:
| - | Technical services, which include:
| ○ | professional radiological measurement and site survey of large government and commercial installations using advanced methods, technology and engineering;
| ○ | health physics services including health physicists, radiological engineers, nuclear engineers and health physics technicians support to government and private radioactive materials licensees;
| ○ | integrated Occupational Safety and Health services including industrial hygiene (“IH”) assessments; hazardous materials surveys, e.g., exposure monitoring; lead and asbestos management/abatement oversight; indoor air quality evaluations; health risk and exposure assessments; health & safety plan/program development, compliance auditing and training services; and Occupational Safety and Health Administration (“OSHA”) citation assistance;
| ○ | global technical services providing consulting, engineering (civil, nuclear, mechanical, chemical, radiological and environmental), project management, waste management, environmental, and decontamination and decommissioning field, technical, and management personnel and services to commercial and government customers; and
| ○ | waste management services to commercial and governmental customers.
| - | Nuclear services, which include:
| ○ | decontamination and decommissioning (“D&D”) of government and commercial facilities impacted with radioactive material and hazardous constituents including engineering, technology applications, specialty services, logistics, transportation, processing and disposal;
| ○ | license termination support of radioactive material licensed and federal facilities over the entire cycle of the termination process: project management, planning, characterization, waste stream identification and delineation, remediation/demo, final status survey, compliance demonstration, reporting, transportation, disposal and emergency response.
| - | A company owned equipment calibration and maintenance laboratory that services, maintains, calibrates, and sources (i.e., rental) health physics, IH and customized nuclear, environmental, and occupational safety and health (“NEOSH”) instrumentation.
| - | A company owned gamma spectroscopy laboratory for the analysis of oil and gas industry solids and liquids.
MEDICAL SEGMENT, which is currently involved on a limited basis in the R&D of the Company’s medical isotope production technology, has not generated any revenue and has substantially reduced its R&D costs and activities due to the need for capital to fund these activities. The Company anticipates that the Medical Segment will not resume full R&D activities until the necessary capital is obtained through its own credit facility or additional equity raise, or obtains partners willing to provide funding for its R&D. Our reporting segments exclude our corporate headquarters and our discontinued operations (see “Note 10 – Discontinued Operations”) which do not generate revenues. The table below presents certain financial information of our operating segments for the three and six months ended June 30, 2021 and 2020 (in thousands): Schedule of Segment Reporting Information Segment Reporting for the Quarter Ended June 30, 2021
|  |  | Treatment |  |  | Services |  |  | Medical |  |  | Segments Total |  |  | Corporate (1) |  |  | Consolidated Total |
Revenue from external customers |  | $ | 7,706 |  |  | $ | 8,439 |  |  |  | — |  |  | $ | 16,145 |  |  | $ | — |  |  | $ | 16,145 |
Intercompany revenues |  |  | 319 |  |  |  | 32 |  |  |  | — |  |  |  | 351 |  |  |  | — |  |  |  | — |
Gross profit (negative gross profit) |  |  | 1,433 |  |  |  | (467 | ) |  |  | — |  |  |  | 966 |  |  |  | — |  |  |  | 966 |
Research and development |  |  | 43 |  |  |  | 19 |  |  |  | 72 |  |  |  | 134 |  |  |  | 10 |  |  |  | 144 |
Interest income |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 2 |  |  |  | 2 |
Interest expense |  |  | (18 | ) |  |  | — |  |  |  | — |  |  |  | (18 | ) |  |  | (47 | ) |  |  | (65 | )
Interest expense-financing fees |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (9 | ) |  |  | (9 | )
Depreciation and amortization |  |  | 310 |  |  |  | 85 |  |  |  | — |  |  |  | 395 |  |  |  | 5 |  |  |  | 400 |
Segment income (loss) before income taxes |  |  | 471 |  |  |  | (1,292 | ) |  |  | (72 | ) |  |  | (893 | ) |  |  | 4,027 | (2) |  |  | 3,134 |
Income tax expense |  |  | 3 |  |  |  | 10 |  |  |  | — |  |  |  | 13 |  |  |  | — |  |  |  | 13 |
Segment income (loss) |  |  | 468 |  |  |  | (1,302 | ) |  |  | (72 | ) |  |  | (906 | ) |  |  | 4,027 |  |  |  | 3,121 |
Expenditures for segment assets |  |  | 270 |  |  |  | 10 |  |  |  | — |  |  |  | 280 |  |  |  | 9 |  |  |  | 289 | (3)
Segment Reporting for the Quarter Ended June 30, 2020
|  |  | Treatment |  |  | Services |  |  | Medical |  |  | Segments Total |  |  | Corporate (1) |  |  | Consolidated Total |
Revenue from external customers |  | $ | 7,840 |  |  | $ | 14,207 |  |  |  | — |  |  | $ | 22,047 |  |  | $ | — |  |  | $ | 22,047 |
Intercompany revenues |  |  | 446 |  |  |  | 5 |  |  |  | — |  |  |  | 451 |  |  |  | — |  |  |  | — |
Gross profit |  |  | 1,695 |  |  |  | 1,615 |  |  |  | — |  |  |  | 3,310 |  |  |  | — |  |  |  | 3,310 |
Research and development |  |  | 52 |  |  |  | 46 |  |  |  | 74 |  |  |  | 172 |  |  |  | 37 |  |  |  | 209 |
Interest income |  |  | 1 |  |  |  | — |  |  |  | — |  |  |  | 1 |  |  |  | 27 |  |  |  | 28 |
Interest expense |  |  | (28 | ) |  |  | (4 | ) |  |  | — |  |  |  | (32 | ) |  |  | (67 | ) |  |  | (99 | )
Interest expense-financing fees |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (60 | ) |  |  | (60 | )
Depreciation and amortization |  |  | 275 |  |  |  | 84 |  |  |  | — |  |  |  | 359 |  |  |  | 5 |  |  |  | 364 |
Segment income (loss) before income taxes |  |  | 750 |  |  |  | 1,031 |  |  |  | (74 | ) |  |  | 1,707 |  |  |  | (1,456 | ) |  |  | 251 |
Income tax benefit |  |  | (9 | ) |  |  | — |  |  |  | — |  |  |  | (9 | ) |  |  | — |  |  |  | (9 | )
Segment income (loss) |  |  | 759 |  |  |  | 1,031 |  |  |  | (74 | ) |  |  | 1,716 |  |  |  | (1,456 | ) |  |  | 260 |
Expenditures for segment assets |  |  | 320 |  |  |  | 146 |  |  |  | — |  |  |  | 466 |  |  |  | 2 |  |  |  | 468 | (4)
Segment Reporting for the Six Months Ended June 30, 2021
|  |  | Treatment |  |  | Services |  |  | Medical |  |  | Segments Total |  |  | Corporate (1) |  |  | Consolidated Total |
Revenue from external customers |  | $ | 15,201 |  |  | $ | 24,077 |  |  |  | — |  |  | $ | 39,278 |  |  | $ | — |  |  | $ | 39,278 |
Intercompany revenues |  |  | 979 |  |  |  | 39 |  |  |  | — |  |  |  | 1,018 |  |  |  | — |  |  |  | — |
Gross profit |  |  | 2,358 |  |  |  | 964 |  |  |  | — |  |  |  | 3,322 |  |  |  | — |  |  |  | 3,322 |
Research and development |  |  | 90 |  |  |  | 32 |  |  |  | 149 |  |  |  | 271 |  |  |  | 24 |  |  |  | 295 |
Interest income |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 21 |  |  |  | 21 |
Interest expense |  |  | (37 | ) |  |  | (8 | ) |  |  | — |  |  |  | (45 | ) |  |  | (87 | ) |  |  | (132 | )
Interest expense-financing fees |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (17 | ) |  |  | (17 | )
Depreciation and amortization |  |  | 620 |  |  |  | 170 |  |  |  | — |  |  |  | 790 |  |  |  | 9 |  |  |  | 799 |
Segment income (loss) before income taxes |  |  | 352 |  |  |  | (737 | ) |  |  | (149 | ) |  |  | (534 | ) |  |  | 2,613 | (2) |  |  | 2,079 |
Income tax (benefit) expense |  |  | (14 | ) |  |  | 10 |  |  |  | — |  |  |  | (4 | ) |  |  | — |  |  |  | (4 | )
Segment income (loss) |  |  | 366 |  |  |  | (747 | ) |  |  | (149 | ) |  |  | (530 | ) |  |  | 2,613 |  |  |  | 2,083 |
Expenditures for segment assets |  |  | 627 |  |  |  | 14 |  |  |  | — |  |  |  | 641 |  |  |  | 9 |  |  |  | 650 | (3)
Segment Reporting for the Six Months Ended June 30, 2020
|  |  | Treatment |  |  | Services |  |  | Medical |  |  | Segments Total |  |  | Corporate (1) |  |  | Consolidated Total |
Revenue from external customers |  | $ | 17,403 |  |  | $ | 29,504 |  |  |  | — |  |  | $ | 46,907 |  |  | $ | — |  |  | $ | 46,907 |
Intercompany revenues |  |  | 653 |  |  |  | 13 |  |  |  | — |  |  |  | 666 |  |  |  | — |  |  |  | — |
Gross profit |  |  | 4,440 |  |  |  | 3,510 |  |  |  | — |  |  |  | 7,950 |  |  |  | — |  |  |  | 7,950 |
Research and development |  |  | 145 |  |  |  | 112 |  |  |  | 140 |  |  |  | 397 |  |  |  | 44 |  |  |  | 441 |
Interest income |  |  | 1 |  |  |  | — |  |  |  | — |  |  |  | 1 |  |  |  | 83 |  |  |  | 84 |
Interest expense |  |  | (46 | ) |  |  | (10 | ) |  |  | — |  |  |  | (56 | ) |  |  | (163 | ) |  |  | (219 | )
Interest expense-financing fees |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (129 | ) |  |  | (129 | )
Depreciation and amortization |  |  | 539 |  |  |  | 162 |  |  |  | — |  |  |  | 701 |  |  |  | 10 |  |  |  | 711 |
Segment income (loss) before income taxes |  |  | 2,297 |  |  |  | 2,349 |  |  |  | (140 | ) |  |  | 4,506 |  |  |  | (2,933 | ) |  |  | 1,573 |
Income tax expense |  |  | 5 |  |  |  | — |  |  |  | — |  |  |  | 5 |  |  |  | — |  |  |  | 5 |
Segment income (loss) |  |  | 2,292 |  |  |  | 2,349 |  |  |  | (140 | ) |  |  | 4,501 |  |  |  | (2,933 | ) |  |  | 1,568 |
Expenditures for segment assets |  |  | 1,000 |  |  |  | 361 |  |  |  | — |  |  |  | 1,361 |  |  |  | 5 |  |  |  | 1,366 | (4)
(1) | Amounts reflect the activity for corporate headquarters not included in the segment information.
(2) | Amounts includes approximately $5,381,000 of “Gain on extinguishment of debt” recorded in connection with the Company’s PPP Loan which was forgiven by the SBA effective June 15, 2021 (see “Note 8 – Long Term Debt – PPP Loan” for information of this loan forgiveness).
(3) | Net of financed amount of $0 and $29,000 for the three and six months ended June 30, 2021, respectively.
(4) | Net of financed amount of $51,000 and $132,000 for the three and six months ended June 30, 2020, respectively.

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 15 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI http://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration